Lantus and Hepatic mass - a phase IV clinical study of FDA data

Summary:

Hepatic mass is reported as a side effect among people who take Lantus (insulin glargine recombinant), especially for people who are male, 60+ old, also take Humalog, and have Insomnia.

The phase IV clinical study analyzes which people have Hepatic mass when taking Lantus. It is created by eHealthMe based on reports of 190,478 people who have side effects when taking Lantus from the FDA, and is updated regularly.

What is Lantus?

Lantus has active ingredients of insulin glargine recombinant. It is often used in diabetes. eHealthMe is studying from 191,782 Lantus users. Check the latest studies of Lantus.

What is Hepatic mass?

Hepatic mass is found to be associated with 405 drugs and 375 conditions by eHealthMe. Check the latest studies of Hepatic mass.

On Jul, 19, 2026

190,478 people reported to have side effects when taking Lantus.
Among them, 29 people (0.02%) have Hepatic mass.

Among these 29 people:

What is the gender of people who have Hepatic mass when taking Lantus? *

female: 44.44 %
male: 55.56 %

What is the age of people who have Hepatic mass when taking Lantus? *

What are other drugs people take besides Lantus? *

What are other side effects people have besides Hepatic mass? *

Joint Pain: 8 people, 27.59%
Stress And Anxiety: 7 people, 24.14%
Back Pain: 7 people, 24.14%
Pain: 7 people, 24.14%
Osteonecrosis Of Jaw (death of bone of jaw): 6 people, 20.69%
Pulmonary Mass: 6 people, 20.69%
Nausea And Vomiting: 6 people, 20.69%
Dyspnea (difficult or laboured breathing): 6 people, 20.69%
Metastases To Liver (cancer spreads to liver): 6 people, 20.69%
Anhedonia (inability to experience pleasure from activities usually found enjoyable): 6 people, 20.69%

What are the existing conditions these people have? *

High Blood Pressure: 4 people, 13.79%
Insomnia (sleeplessness): 4 people, 13.79%
Idiopathic Pulmonary Fibrosis (chronic lung disease): 2 people, 6.90%
Multiple Myeloma (cancer of the plasma cells): 2 people, 6.90%
Chronic Myeloid Leukaemia (long lasting type of cancer that starts in the blood-forming cells of the bone marrow and invades the blood): 2 people, 6.90%
Glaucoma (increased fluid pressure in the eye with vision loss): 2 people, 6.90%
High Blood Cholesterol: 2 people, 6.90%
Vitamin B12 Deficiency: 2 people, 6.90%
Metastases To Bone (cancer spreads to bone): 2 people, 6.90%
Allergic Rhinitis: 2 people, 6.90%

* Approximation only. Some reports may have incomplete information.

Do you take Lantus and have Hepatic mass?

- Check whether Hepatic mass is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Lantus:

Lantus (191,782 reports)

Hepatic mass treatments and more:

Hepatic mass (2,425 reports)

Browse all side effects of Lantus:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Hepatic mass:

Hepatic mass (405 drugs)

Browse all the conditions that are associated with Hepatic mass:

Hepatic mass (375 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on insulin glargine recombinant (the active ingredients of Lantus) and Lantus (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.